S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:NXTC

NextCure (NXTC) Stock Price, News & Analysis

$2.23
+0.29 (+14.95%)
(As of 03/28/2024 ET)
Today's Range
$1.82
$2.28
50-Day Range
$1.13
$2.23
52-Week Range
$0.98
$2.28
Volume
1.02 million shs
Average Volume
254,669 shs
Market Capitalization
$62.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

NextCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
169.1% Upside
$6.00 Price Target
Short Interest
Healthy
3.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.29mentions of NextCure in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.80) to ($1.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.55 out of 5 stars

Medical Sector

102nd out of 938 stocks

Biotechnology Industry

1st out of 34 stocks

NXTC stock logo

About NextCure Stock (NASDAQ:NXTC)

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NXTC Stock Price History

NXTC Stock News Headlines

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
NextCure Provides Year-End Clinical Pipeline Updates
NextCure Inc NXTC
See More Headlines
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NXTC
Fax
N/A
Employees
82
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+169.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-62,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.10 per share

Miscellaneous

Free Float
24,583,000
Market Cap
$62.22 million
Optionable
Optionable
Beta
0.37
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael S. Richman MSBA (Age 63)
    Co-Founder, CEO, President & Director
    Comp: $713.95k
  • Dr. Solomon Langermann Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $538.62k
  • Dr. Han Myint FACP (Age 71)
    M.D., Chief Medical Officer
    Comp: $554.46k
  • Dr. Lieping Chen M.D. (Age 66)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Steven P. Cobourn CPA (Age 61)
    Chief Financial Officer
    Comp: $313.25k
  • Dr. Timothy Mayer Ph.D. (Age 59)
    Chief Operating Officer
  • Mr. Kevin G. Shaw (Age 50)
    General Counsel
  • Ms. Stacy Rollinger
    Vice President of Human Resources
  • Mr. Sourav Kundu Ph.D. (Age 64)
    Senior Vice President of Development & Manufacturing
  • Dr. Sebastien Maloveste
    Senior Vice President of Business Development

NXTC Stock Analysis - Frequently Asked Questions

Should I buy or sell NextCure stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares.
View NXTC analyst ratings
or view top-rated stocks.

What is NextCure's stock price target for 2024?

2 analysts have issued 1-year price objectives for NextCure's stock. Their NXTC share price targets range from $4.00 to $8.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 169.1% from the stock's current price.
View analysts price targets for NXTC
or view top-rated stocks among Wall Street analysts.

How have NXTC shares performed in 2024?

NextCure's stock was trading at $1.14 at the start of the year. Since then, NXTC stock has increased by 95.6% and is now trading at $2.23.
View the best growth stocks for 2024 here
.

Are investors shorting NextCure?

NextCure saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 839,700 shares, an increase of 579.9% from the February 29th total of 123,500 shares. Based on an average trading volume of 229,500 shares, the short-interest ratio is presently 3.7 days. Approximately 4.0% of the company's shares are sold short.
View NextCure's Short Interest
.

When is NextCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NXTC earnings forecast
.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) announced its earnings results on Thursday, November, 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.02.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), Organigram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?

NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

Who are NextCure's major shareholders?

NextCure's stock is owned by many different institutional and retail investors. Top institutional investors include Cable Car Capital LLC (2.21%), Acuitas Investments LLC (1.34%), Federated Hermes Inc. (1.18%), Dimensional Fund Advisors LP (0.31%), ADAR1 Capital Management LLC (0.22%) and Marquette Asset Management LLC (0.21%).
View institutional ownership trends
.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NXTC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners